Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 17,600 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the sale, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. This trade represents a 14.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $1.83 on Wednesday, hitting $48.86. The company had a trading volume of 547,438 shares, compared to its average volume of 400,256. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $49.09. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27. The company has a market cap of $1.54 billion, a PE ratio of 30.35 and a beta of 0.61. The business has a 50-day simple moving average of $39.86 and a 200-day simple moving average of $35.61.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The firm had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%. Research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL acquired a new position in shares of Collegium Pharmaceutical in the third quarter worth about $560,000. NewEdge Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 535.9% during the third quarter. NewEdge Advisors LLC now owns 19,376 shares of the specialty pharmaceutical company’s stock valued at $678,000 after acquiring an additional 16,329 shares during the period. Caxton Associates LLP purchased a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $961,000. Dark Forest Capital Management LP purchased a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $1,226,000. Finally, XTX Topco Ltd acquired a new position in Collegium Pharmaceutical in the 3rd quarter worth approximately $547,000.

Wall Street Analyst Weigh In

COLL has been the subject of several research analyst reports. HC Wainwright upped their price objective on Collegium Pharmaceutical from $44.00 to $46.00 and gave the company a “buy” rating in a report on Friday, November 7th. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Zacks Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Friday, November 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th. Finally, Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $47.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.